Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: IART (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 2 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.92% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05B USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 12 | Beta 1.08 | 52 Weeks Range 10.87 - 27.13 | Updated Date 12/4/2025 |
52 Weeks Range 10.87 - 27.13 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.15% | Operating Margin (TTM) 9.92% |
Management Effectiveness
Return on Assets (TTM) 2.61% | Return on Equity (TTM) -38.71% |
Valuation
Trailing PE - | Forward PE 5.35 | Enterprise Value 2755251969 | Price to Sales(TTM) 0.64 |
Enterprise Value 2755251969 | Price to Sales(TTM) 0.64 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA 14.27 | Shares Outstanding 77892111 | Shares Floating 58997822 |
Shares Outstanding 77892111 | Shares Floating 58997822 | ||
Percent Insiders 13.96 | Percent Institutions 95.14 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences Holdings Corporation was founded in 1989. It has grown through organic growth and acquisitions to become a leading provider of surgical and regenerative medicine solutions.
Core Business Areas
- Codman Specialty Surgical (CSS): Develops, manufactures, and markets a broad range of products for neurosurgery, dural repair, and advanced energy surgical devices.
- Tissue Technologies: Focuses on regenerative technologies, including skin and wound care, soft tissue repair, and orthopedics. Features products based on collagen and other natural materials.
Leadership and Structure
Integra LifeSciences is led by Jan De Witte (President and CEO). The company has a board of directors overseeing its corporate governance.
Top Products and Market Share
Key Offerings
- DuraGen: Dural repair product used in neurosurgery. Integra holds a significant market share in the dural repair market, estimated around 30-40%. Competitors include Medtronic and Johnson & Johnson (DePuy Synthes).
- CASH System: A radiofrequency ablation system used in neurosurgery. Competitors include Medtronic and Stryker. Market data and revenue from this product is not publicly disclosued.
- Integra Bilayer Matrix Wound Dressing: Wound care product used for burns and chronic wounds. It competes with products from Smith+Nephew, Molnlycke Health Care, and 3M.
Market Dynamics
Industry Overview
The surgical and regenerative medicine market is characterized by innovation, driven by an aging population, increasing demand for minimally invasive procedures, and advancements in biomaterials.
Positioning
Integra LifeSciences is a key player, known for its strong presence in neurosurgery and regenerative medicine. Its competitive advantage lies in its broad product portfolio and established relationships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market for Integra LifeSciences's products is estimated to be in the billions of dollars. Integra holds a good position within this TAM, with a scope of potential growth as markets and products develop.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in neurosurgery
- Diversified product portfolio
- Established distribution network
- Experience in acquiring and integrating companies
Weaknesses
- Dependence on key products
- Exposure to pricing pressures
- Risk of product recalls
- Integration risk from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new regenerative medicine products
- Acquiring complementary businesses
- Advancing technologies in minimally invasive procedures
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- SNY
Competitive Landscape
Integra has advantages in neurosurgery and regenerative medicine. However, competitors have broader product portfolios and greater financial resources.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Explain the strategic reasons behind the acquisition.
Growth Trajectory and Initiatives
Historical Growth: Integra LifeSciences has grown steadily through organic growth and strategic acquisitions.
Future Projections: Future growth is projected to be driven by continued demand for its surgical and regenerative medicine products, particularly in emerging markets.
Recent Initiatives: Recent initiatives include new product launches, strategic acquisitions, and investments in research and development.
Summary
Integra LifeSciences is a solid company, with a focus on neurosurgery and regenerative medicine and holds a good position in the surgical area of medicine. Its acquisitions are strategic for growth. The company needs to be aware of competative pressure and regulatory changes. Growth can be achieved by expanding to emerging markets and developing regenerative medicine products.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.